10 February 2026
EMA/33615/2026
Committee for Veterinary Medicinal Products (CVMP)

Committee for Veterinary Medicinal Products

Minutes of the 13-15 January 2026 meeting

Chair: G. J. Schefferlie – Vice-chair: F. Hasslung Wikström

13 January 2026, 09:00 – 15 January 2026, 13:00 - Room 1C and virtual

Health & Safety Information

In accordance with **Note on access to documents**

Some documents mentioned in the minutes cannot be released at present within the framework of Regulation (EC) No 1049/2001 on access to documents because they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/729522/2016).

The meeting was held in-person.

i. Adoption of the Agenda

The Committee adopted the agenda with no modifications.

ii. Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CVMP plenary session 13-15 January 2026

The attendance list was completed and competing interests were identified for the January 2026 meeting. In accordance with the Agency's policy and procedure on the handling of competing interests, participants in this meeting were asked to declare any interests on the matters discussed (in particular any changes, omissions or errors to the already declared interests). Discussions, deliberations and voting took place in full respect of the restricted involvement of CVMP members and, where relevant, experts attending the plenary meeting, as announced by the CVMP secretariat at the start of the meeting (see Annex I).

iii. Declaration of contacts between members and companies with regard to points on the agenda

Information relating to declared contacts between members and companies with regard to points on the agenda cannot be released at the present time as it is deemed to be commercially confidential.

No contacts have been declared.

iv. Adoption of the minutes of the previous meeting

The adoption of minutes of the December 2025 meeting was postponed to February.

v. Topics for rapporteur's meetings, break-out sessions held in advance or in the margins of the present CVMP meeting

Information relating to briefing meetings taking place with applicants/marketing authorisation holders cannot be released at the present time as it is deemed to be commercially confidential.

1. Maximum residue limits

1.1. Opinions

No items

1.2. Oral explanations

No items

1.3. List of outstanding issues

No items

1.4. List of questions

No items

1.5. Re-examination of CVMP opinions on maximum residue limits

No items

1.6. Other issues

No items

2. Marketing authorisations

2.1. Opinions

2.1.1. Lotilaner / Milbemycin Elanco – lotilaner / milbemycin oxime - EMEA/V/C/006911/0000 – dogs

Indication: for use in dogs with, or at risk from, mixed infestations/infections by ticks, fleas, mites, gastrointestinal nematodes, heartworm and/or lungworm.

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion, the CVMP assessment report and the product information.

Action: For information

The Committee noted the summary of opinion and a peer review report.

2.2. Oral explanations

No items

2.3. List of outstanding issues

2.3.1. *Salmonella Infantis* vaccine (live) – EMEA/V/C/006646/0000 – chickens

Indication: for active immunisation of chickens to reduce organ colonization and faecal excretion due to *Salmonella Infantis.*

Action: For decision

The Committee agreed that no oral explanation was needed.

Action: For adoption

The Committee adopted the scientific overview and list of outstanding issues and the comments on the product information.

Action: For information

The Committee noted two peer review reports and the comments from GMO authorities.

2.3.2. Bluetongue virus vaccine (inactivated) - EMEA/V/C/006821/0000 – sheep, cattle

Indication: for active immunisation of sheep to reduce viraemia, preventing mortality and to reduce clinical signs caused by the serotype 3 of the bluetongue virus. For active immunisation of cattle against the serotype 3 of the bluetongue virus.

Accelerated assessment

Action: For decision

The Committee agreed that no oral explanation was needed.

Action: For adoption

The Committee adopted the scientific overview and list of outstanding issues and the comments on the product information.

Action: For information

The Committee noted two peer review reports and comments from a CVMP member.

2.3.3. Velagliflozin - EMEA/V/C/006610/0000 – horses

Indication: for the treatment of hyperinsulinaemia and associated clinical signs (e.g., laminitis) in insulin-dysregulated horses and ponies not responsive to changes in husbandry and exercise regimen.

Action: For decision

The Committee agreed that an oral explanation was needed. It expected to take place in March 2026.

Action: For adoption

The Committee adopted the scientific overview and list of outstanding issues and comments on the product information.

Action: For information

The Committee noted two peer review reports.

2.4. List of questions

No items

2.5. Re-examinations of CVMP opinions

No items

2.6. Other issues

2.6.1. Canine adipose-derived mesenchymal stem cells - EMEA/V/C/006457/0000 – dogs

Action: For endorsement

The Committee endorsed the request from the applicant for an extension of clock stop.

2.6.2. Verdinexor - EMEA/V/C/005902 – dogs

Action: For endorsement

The Committee endorsed the request from the applicant for an extension of clock stop.

3. Variations to marketing authorisations

3.1. Opinions

No items

3.2. Oral explanations

No items

3.3. List of outstanding issues

No items

3.4. List of questions

3.4.1. RESPIVAC aMPV – turkey rhinotracheitis virus, live - EMA/VRA/0000309778 – chickens

Variation requiring assessment: I.III.1.a – to add turkeys as a new target species; G.I.4 – to establish a higher minimum composition per dose in chickens than the one currently authorised. Additionally, the product information is aligned with version 9.1 of the QRD template.

Rapporteur: E. Werner, Co-Rapporteur: C. Miras

Action: For adoption

The Committee adopted the list of questions and scientific overview, and comments on the product information.

3.5. Re-examinations of CVMP opinions on variations requiring assessment

No items

3.6. Other issues

3.6.1 Cirbloc M Hyo – porcine circovirus and porcine enzootic pneumonia vaccine (inactivated) - EMA/VRA/0000288333 – pigs

Rapporteur: K. Baptiste

Action: For endorsement

The Committee endorsed the request from the applicant for an extension of clock stop.

4. Referrals and related procedures

4.1. Union interest referral under Article 82 of Regulation (EU) 2019/6

No items

4.2. Union interest referral under Article 82 based on Article 129(3) of Regulation (EU) 2019/6

No items

4.3. Procedure under Article 70(11) of Regulation (EU) 2019/6 due to lack of consensus between Member States in the SPC harmonisation procedure

No items

4.4. Request for clarification from the European Commission under Article 54(8) of Regulation (EU) 2019/6 on a CMDv review procedure

No items

4.5. Request from the European Commission under Article 130(4) of Regulation (EU) 2019/6 on suspending, revoking or varying the terms of centrally authorised products

No items

4.6. Request for a scientific opinion/advice under Articles 141(1)(c), 141(1)(e) or 141(1)(i) of Regulation (EU) 2019/6

No items

4.7. Other issues

Information on certain topics discussed under section 4.7 cannot be released at the present time as it is deemed to be confidential

No items

5. Post-authorisation issues for marketing authorisations

Information relating to GMP, pharmacovigilance inspections, supervision and sanctions will not be published as it would undermine the purpose of such inspections.

5.1. Pharmacovigilance

No items

5.2. Post-authorisation measures

No items

5.3. Inspections and controls

No items

5.4. Re-examination of limited markets and exceptional circumstances authorisations

5.4.1. Syvazul BTV 3 – Bluetongue virus vaccine (inactivated) - EMA/S/0000309717

Re-examination of the marketing authorisation for Syvazul BTV 3 in line with Article 27(3) of Regulation (EU) 2019/6.

Rapporteur: R. Breathnach, Co-Rapporteur: J. Poot

Action: For adoption

The Committee adopted the list of questions.

Action: For information

The Committee noted the rapporteur's assessment report and the comments from the CVMP members.

5.4.2. Bluevac-3 – Bluetongue virus vaccine (inactivated) - EMA/S/0000310022

Re-examination of the marketing authorisation for Bluevac-3 in line with Article 27(3) of Regulation (EU) 2019/6.

Rapporteur: E. Werner, Co-Rapporteur: C. Muñoz Madero

Action: For adoption

The Committee adopted the CVMP opinion, the CVMP assessment report and the product information, recommending the extension for one year of the validity of the marketing authorisation in exceptional circumstances.

5.5. Other issues

No items

6. Working parties

Information relating to certain topics discussed under section 6 cannot be released at the present time as it is deemed to be commercially confidential.

6.1. Antimicrobials Working Party (AWP)

6.1.1. Verbal report on AWP meeting held on 9-10 December 2025

Action: For information

The Committee received a verbal report on the AWP meeting held on 9-10 December 2025 and noted its agenda together with the minutes of the meeting held on 23-24 September 2025.

6.2. Environmental Risk Assessment Working Party (ERAWP)

6.2.1. Concept paper for the development of a guideline on the methodology of environmental risk assessment for ectoparasiticidal VMPs for cats and dogs

Action: For discussion

The Committee discussed the concept paper for the development of a guideline on the methodology of environmental risk assessment for parasiticidal VMPs for cats and dogs and the overview of comments received on the concept paper during public consultation. The topic will be further discussed in February.

6.3. Efficacy Working Party (EWP-V)

6.3.1. Guideline for the evaluation of efficacy of ectoparasiticides - general requirements

Action: For adoption

The Committee adopted the revised guideline for the evaluation of efficacy of ectoparasiticides - general requirements (EMA/CVMP/EWP/507106/2023) for release for a 4-month period of public consultation.

6.3.2. Guideline on veterinary medicinal products controlling *Varroa destructor* parasitosis in bees

Action: For adoption

The Committee adopted the revised guideline on veterinary medicinal products controlling Varroa destructor parasitosis in bees (EMA/CVMP/EWP/459883/2008-Rev.2) for release for a 4-month period of public consultation.

6.3.3. Concept paper on the development of a guideline for using owner assessment as efficacy parameter

Action: For adoption

The Committee adopted the concept paper on the development of a guideline for using owner assessment as efficacy parameter (EMA/CVMP/EWP/364649/2025) for release for a 3-month period of public consultation.

6.4. Immunologicals Working Party (IWP)

6.4.1. Revision of the guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs)

Action: For adoption

The Committee adopted the revised guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs).

6.4.2. Revision of IWP guidelines to align with Regulation (EU) 2019/6

Action: For adoption

The Committee adopted the revised guideline on environmental risk assessment for immunological veterinary medicinal products, the revised guideline on user safety for immunological veterinary medicinal products and the revised guideline on the design of studies to evaluate the safety and efficacy of fish vaccines.

6.5. 3Rs Working Party (3RsWP)

6.5.1. Verbal report on 3RsWP meeting held on 19-20 November 2025

Action: For information

The Committee received a verbal report on 3RsWP meeting held on 19–20 November 2025 and noted its agenda.

6.6. Novel Therapies & Technologies Working Party (NTWP)

6.6.1. Novel therapies ESEC

Action: For adoption

The Committee adopted the mandate of the novel therapies ESEC. The document will be presented to CHMP and CAT, after which a call for nominations will be launched.

6.7. Pharmacovigilance Working Party (PhVWP-V)

6.7.1. Concept paper for the revision of the Guideline on veterinary good pharmacovigilance practices (VGVP) Module: signal management

Action: For discussion

The Committee discussed the draft concept paper on revision of the VGVP on signal management. The concept paper is expected to be adopted by February.

6.8. Quality Working Party (QWP)

6.8.1. Revised Question and answer on titanium dioxide

Action: For adoption

The Committee adopted the updated Q&A on TiO_2 (titanium dioxide).

6.8.2. Questions and answers on co-processed excipients

Action: For adoption

The Committee adopted the Q&A on co-processed excipients and the overview of comments.

6.8.3. Revised Question and answer on 'How to use a CEP'

Action: For adoption

The Committee adopted the updated Q&A on How to use a CEP.

6.8.4. Revised Quality of medicines questions and answers

Action: For adoption

The Committee adopted the revised Quality of medicines questions and answers: Part 1 and Part 2.

6.8.5. Revised Question and answer on complex manufacturing processes

Action: For discussion

The Committee discussed the updated Q&A on complex manufacturing processes. Adoption is expected at the February CVMP meeting.

6.9. Scientific Advice Working Party (SAWP-V)

6.9.1. Verbal report on SAWP-V meeting held on 9 January 2026

Action: For information

The Committee received a verbal report on SAWP-V meeting held on 9 January 2026 and noted its agenda together with the final minutes of the SAWP-V meeting held on 28 November 2025.

6.10. Safety Working Party (SWP-V)

No items

6.11. Other working party and scientific group issues

7. Other scientific matters

Information on scientific matters or other critical issues cannot be released at the present time as it is deemed to be confidential

7.1. MRL issues

No items

7.2. Environmental risk assessment

No items

7.3. Antimicrobial resistance

No items

7.4. Pharmacovigilance

No items

7.5. Vaccine antigen master file (VAMF) certification

Information on this section cannot be released at the present time as it is deemed to be commercially confidential.

No items

7.6. Platform technology master file (PTMF) certification

Information on this section cannot be released at the present time as it is deemed to be commercially confidential.

No items

7.7. Other issues

No items

8. Co-operation with other EU or International bodies

Information on certain topics discussed under section 8 cannot be released at the present time as it is deemed to be commercially confidential.

8.1. VICH

8.1.1. Concept paper for revision of VICH GL47 on Comparative Metabolism Studies in Laboratory Animals

Action: For discussion

The Committee discussed the concept paper for revision of VICH GL47 on Comparative Metabolism Studies in Laboratory Animals and the need to appoint an adviser to work on the EU positions relevant to the revision. The guideline focuses on in vitro cell culture techniques, particularly with hepatocytes.

8.1.2. Revision of VICH GL8 on Stability Testing for Medicated Premixes

Action: For agreement

8.2. Draft status report including EU comments Codex Alimentarius

No items

8.3. Other EU bodies and international organisations

No items

9. Procedural and regulatory matters

Information relating to limited markets classifications, new applications and eligibility requests for Union marketing authorisations and certain regulatory matters cannot be released at the present time as it is deemed to be commercially confidential.

9.1. Limited markets classifications according to Article 4(29) and confirmation of eligibility for authorisation according to Article 23 of Regulation (EU) 2019/6

9.1.1. Request for classification

Action: For classification

The Committee discussed the veterinary medicinal product for horses. The Committee agreed that the product is classified as limited market but not eligible for article 23.

9.2. Eligibility for centralised procedures, appointment of rapporteurs, co-rapporteurs and peer reviewers

No items

9.3. Regulatory matters

No items

10. Organisational and strategic matters

10.1. Veterinary Domain verbal report on meeting held on 15 December 2025

Action: For information

The Committee received a veterinary domain verbal report on meeting held on 15 December 2025 and noted its agenda together with the minutes of the 16 September 2025 meeting.

10.2. Revision of the Mandate, objectives and rules of procedure for the Veterinary Domain

Action: For discussion

The Committee discussed the Mandate, objectives and rules of procedure for the Veterinary Domain. The adoption is expected to take place at the February CVMP meeting.

11. CMDv

No items

12. Legislation

12.1. European Commission's request under Article 141(1)(f) of Regulation (EU) 2019/6: guidance on scientific issues in relation to Articles 107(6) and 114(3)

Action: For endorsement

The Committee endorsed P. McNeill to act as rapporteur and H. Bergendahl to act as co-rapporteur, and noted the participation of D. Palic, D. Persson and T. Hoy to join as experts for the European Commission's request.

13. Any other business

13.2. Meeting highlights

Action: For comments

Meeting highlights (link)

14. Annex

3. Variations to marketing authorisations

3.1. Opinions

Vectormune ND/Vectormune HVT-AIV/Newflend ND H9/Ultifend ND IBD (WS) – EMA/VRA/0000292249 – chickens

Variation requiring assessment: quality-related changes.

Rapporteur: J. Poot

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

Versican Plus DHPPi/L4R/Versican Plus DHPPi/L4/Versican Plus DHPPi /Versican Plus Pi /Versican Plus Pi/L4R/Versican Plus Pi/L4 (WS) – EMA/VRA/0000290574 – dogs

Variation requiring assessment: quality-related changes.

Rapporteur: E. Werner

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

Strangvac – *Streptococcus equi* vaccine (recombinant proteins) - EMA/VRA/0000309871 – horses

Variation requiring assessment: quality-related changes.

Rapporteur: M. Blixenkrone-Møller

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

Arti-Cell Forte – alisvetcel - EMA/VRA/0000310983 – horses

Variation requiring assessment: quality-related changes.

Rapporteur: F. Hasslung Wikström

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

Librela / Equip WNV / Suvaxyn CSF Marker / Suvaxyn Circo+MH RTU / Cytopoint / Suvaxyn Circo / Suvaxyn PRRS MLV / CircoMax / CircoMax Myco/Solensia and NAPs (WS) - EMA/VRA/0000295122 – dogs, horses, pigs, cats

Variation requiring assessment: quality-related changes.

Rapporteur: N.C. Kyvsgaard

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

Improvac and NAPs (WS) - EMA/VRA/0000295128 – pigs

Variation requiring assessment: quality-related changes.

Rapporteur: N.C. Kyvsgaard

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

Purevax RCPCh FeLV, Purevax RCPCh– Feline calicivirosis vaccine (inactivated), feline viral rhinotracheitis, feline infectious enteritis (feline panleucopenia), feline chlamydiosis vaccine (live) and feline leukaemia vaccine (live recombinant) - EMA/VRA/0000293649 – cats

Variation requiring assessment: quality-related changes.

Rapporteur: E. Dewaele

Action: For adoption

The Committee adopted, by consensus, the CVMP opinion.

Action: For endorsement

The Committee endorsed the rapporteur's assessment report.

3.4. List of questions

Coxevac – *Coxiella burnetii* vaccine (inactivated) - EMA/VRA/0000308623 – cattle, goats, sheep

Variation requiring assessment: quality-related changes.

Rapporteur: C. Miras

Action: For adoption

The Committee adopted the list of questions.

Versican Plus DHPPi/L4R, Versican Plus DHPPi/L4, Versican Plus L4, Versican Plus Pi/L4, Versican Plus Pi/L4R (WS) - EMA/VRA/0000293810 – dogs

Variation requiring assessment: quality-related changes.

Rapporteur: E. Werner

Action: For adoption

The Committee adopted the list of questions and the comments on the product information of: Versican Plus DHPPi/L4R, Versican Plus DHPPi/L4, Versican Plus L4, Versican Plus Pi/L4, Versican Plus Pi/L4R .

Bluevac BTV - Bluetongue virus vaccine (inactivated) - EMA/VRA/0000309935 – cattle and sheep

Variation requiring assessment: quality-related changes.

Rapporteur: E. Werner

Action: For adoption

The Committee adopted the list of questions and the comments on the product information.

Vectormune ND/Vectormune FP ILT + AE/Vectormune HVT-AIV/Newflend ND H9/Ultifend ND IBD/ Vectormune FP ILT (WS) – EMA/VRA/0000290574 – chickens

Variation requiring assessment: quality-related changes.

Rapporteur: J. Poot

Action: For adoption

The Committee adopted the list of questions.

Zenrelia – ilunocitinib - EMA/VRA/0000309679 – dogs

Variation requiring assessment: quality-related changes.

Rapporteur: R. Breathnach

Action: For adoption

The Committee adopted the list of questions.

Halagon – halofuginone - EMA/VRA/0000309721 – cattle

Variation requiring assessment: to align the product information with version 9.1 of the QRD template.

Rapporteur: C. Muñoz Madero

Action: For adoption

The Committee adopted the list of questions and the comments on the product information.

Cimalgex and NAPs (WS) – EMA/VRA/0000295102 – dogs

Variation requiring assessment: Quality-related changes.

Rapporteur: H. Bremer

Action: For adoption

The Committee adopted the CVMP opinion.

3.6. Other issues

Mometamax Ultra - gentamicin / posaconazole / mometasone furoate - EMA/VRA/0000300844 – dogs

Rapporteur: K. Baptiste, Co-Rapporteur: S. Louet

Action: For endorsement

The Committee endorsed the request from the applicant for an extension of clock stop.

4. Referrals and related procedures

4.7. Other issues

5. Post-authorisation issues for marketing authorisations

5.3. Inspections and controls under Regulation (EU) 2019

6. Working parties

6.2 Environmental Risk Assessment Working Party (ERAWP)

ERA ESEC Nominations

Action: For adoption

The Committee adopted the ERA ESEC Expert nominations.

6.8 Quality Working Party (QWP)

Quality Chemical ESEC nominations

Action: For adoption

The Committee adopted the nominations for the Quality Chemical ESEC.

7. Other scientific matters

7.7. Other issues

Status report of evaluations for the establishment of new MRLs

Action: For information

The Committee noted the status report of evaluations for the establishment of new MRLs.

8. Co-operation with other EU or International bodies

8.1. VICH

9. Procedural and regulatory matters

9.1. Limited markets classifications according to Article 4(29) and confirmation of eligibility for authorisation according to Article 23 of Regulation (EU) 2019/6

9.3. Regulatory matters

Invented names

11. CMDv

Reports from CMDv

Action: To note

The Committee noted the final agenda of the CMDv meeting held on 10-11 December 2025.

ANNEX I

List of participants including any restrictions with respect to involvement of members/alternates/ experts following evaluation of declared interests for the 13-15 January 2026 CVMP meeting, which was held in person.

An asterisk (*) after the name, in the first column, signals that the participant attended remotely.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of DoI	Topics for which restriction apply
G. Johan Schefferlie	**Chair**	**CHAIR**	**No interests declared**	
Petra Falb	Member	Austria	No restrictions applicable to this meeting	
Manuela Leitner*	Alternate	Austria	No interests declared	
Els Dewaele	Member	Belgium	No interests declared	
Krasimir Zlatkov	Member	Bulgaria	No interests declared	
Leona Nepejchalová	Member	Czechia	No interests declared	
Niels Christian Kyvsgaard*	Member	Denmark	No interests declared	
Merete Blixenkrone-Møller	Alternate	Denmark	No interests declared	
Minna Leppänen	Member	Finland	No interests declared	
Sylvie Louet	Member	France	No interests declared	
Christine Miras	Alternate	France	No interests declared	
Andrea Christina Golombiewski*	Member	Germany	No restrictions applicable to this meeting	
Esther Werner	Alternate	Germany	No interests declared	
Spyridon Farlopoulos	Member	Greece	No interests declared	
Gábor Kulcsár	Member	Hungary	No participation in discussion, final deliberations and voting on:	EMA/SA/0000303347 EMEA/V/C/006610/0000 EMA/VRA/0000310983 EMA/VRA/0000293649

Name	Role	Member state or affiliation	Outcome restriction following evaluation of DoI	Topics for which restriction apply
Paul McNeill	Member	Ireland	No interests declared	
Alice Blennerhassett*	Alternate	Ireland	No interests declared	
Fulvio Marsilio	Member	Italy	No interests declared	
Renate Kuske*	Alternate	Latvia	No restrictions applicable to this meeting	
Vaida Kurapkiene*	Alternate	Lithuania	No restrictions applicable to this meeting	
Despoina Iatridou*	Alternate	Luxembourg	No interests declared	
Kim Boerkamp*	Alternate	Netherlands	No restrictions applicable to this meeting	
Ewa Augustynowicz*	Alternate	Poland	No interests declared	
Marcin Glanda	Alternate	Poland	No interests declared	
João Pedro Duarte Da Silva*	Member	Portugal	No interests declared	
Gabriela Tuchila	Member	Romania	No interests declared	
Eva Chobotová*	Member	Slovakia	No interests declared	
Mojca Ogriz*	Alternate	Slovenia	No interests declared	
Urska Peunik	Member	Slovenia	No interests declared	
Cristina Muñoz Madero	Member	Spain	No interests declared	
Frida Hasslung Wikström	Member (Vice-Chair)	Sweden	No interests declared	
Hanna Bremer	Alternate	Sweden	No interests declared	
Ricardo Carapeto García	Co-opted member	Spain	No interests declared	
Rory Breathnach*	Co-opted member	Ireland	No restrictions applicable to this meeting	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of DoI	Topics for which restriction apply
Mary O'Grady	Co-opted member	Ireland	No interests declared	
Carina Bergman	Co-opted member	Sweden	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of DoI	Topics on agenda for which restrictions apply
Mariette Salery	Expert	France	No interests declared	
Rosario Bullido	Expert	Spain	No interests declared	
Alberto de Prado Lopez	Expert	Spain	No interests declared	
Carlos Ballesteros	Expert	Spain	No interests declared	
Leyre Sánchez Sánchez de Rojas	Expert	Spain	No interests declared	
Veronica Devesa	Expert	Spain	No interests declared	
Lorena Touriño González	Expert	Spain	No interests declared	
Ana Isabel Olías Molero	Expert	Spain	No interests declared	
Mark Montforts	Expert	Netherlands	No interests declared	
Philippe Berny	Expert	France	No restrictions applicable to this meeting	
Haru Kroneis	Expert	Austria	No interests declared	
Nathalie Bridoux	Expert	France	No interests declared	
Luis Agote Casado	Expert	Spain	No interests declared	
Sonia Gil Morales	Expert	Spain	No interests declared	
Kathrin Schirmann	Expert	Germany	No interests declared	
Daniel Benesh	Expert	Germany	No interests declared	
Christian Kühne	Expert	Germany	No interests declared	
Frida Martin	Expert	Sweden	No interests declared	
Hannah Pratt	Expert	Ireland	No interests declared	
Rhona McHugh	Expert	Ireland	No interests declared	
Emily Hams	Expert	Ireland	No interests declared	
Sarah Buckley	Expert	Ireland	No interests declared	
Kathrine Just Andersen	Expert	Denmark	No interests declared	
Anja Silke Christensen	Expert	Denmark	No interests declared	
Nuria Doñamayor Alonso	Expert	Germany	No restrictions applicable to this meeting	
Miriam Schrader	Expert	Germany	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of DoI	Topics on agenda for which restrictions apply
Viviane Filor	Expert	Germany	No restrictions applicable to this meeting	
Laura Kulisch	Expert	Germany	No interests declared	
Lucas Praetorius	Expert	Germany	No restrictions applicable to this meeting	
Maren Osmers	Expert	Germany	No interests declared	
Neele Puhlmann	Expert	Germany	No restrictions applicable to this meeting	
Monika Hofmann	Expert	Germany	No interests declared	
Sandra Schack	Expert	Germany	No interests declared	
Heike Gyra	Expert	Germany	No interests declared	
Ingun Lemke	Expert	Germany	No interests declared	
Daniela Loos	Expert	Germany	No interests declared	
Henriette Rau	Expert	Germany	No interests declared	
Dagmar Sommer	Expert	Germany	No interests declared	
Brigitte Kuechler	Expert	Germany	No interests declared	
Rodrigo García Fernández	Expert	Spain	No restrictions applicable to this meeting	
Erik den Hertog	Expert	Netherlands	No restrictions applicable to this meeting	

An asterisk (*) after the name, in the first column, signals that the participant attended in person.

CVMP working parties and CMDv	Chair
AWP	Damien Bouchard
IWP	Esther Werner*
QWP	Marie-Hélène Sabinotto *(veterinary vice chair)*
SAWP-V	Frida Hasslung Wikström*
SWP-V	Carina Bergman*
EWP	Cristina Muñoz Madero*
ERAWP	Mark Montforts
Observers from SwissMedic (Switzerland) attended the meeting	
A representative from the European Commission attended the meeting	
Meeting run with support from the relevant EMA staff.	

An asterisk (*) after the name, in the second column, signals that the participant attended in person

Experts' declared interests were evaluated against the agenda topics or activities they participated in.